Gino In

Associate Professor of Clinical Medicine

Image of Gino In
Is this your profile? Click to edit

Overview

Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

Awards

  • University of Southern California: Chief Medical Oncology Fellow

Education and Training

  • University of Southern California, Los Angeles, CA — Fellowship — 2016 — Hematology/Oncology
  • SUNY Downstate Medical Center, Brooklyn, NY — Residency — 2011 — Internal Medicine
  • SUNY Downstate Medical Center, Brooklyn, NY — Internship — 2010
  • Ross University, North Brunswick Township, NJ — MD — 2010 — Medicine
  • Emory University, Atlanta, GA — MPH — 2006 — Environmental/Occupational Health
  • Emory University, Atlanta, GA — BS — 2002

Research Keywords

  • Medical Oncology
  • Skin Cancer
  • Melanoma
  • Acral Lentiginous Melanoma
  • Uveal Melanoma
  • Mucosal Melanoma
  • Squamous Cell Carcinoma
  • Basal Cell Carcinoma
  • Merkel Cell Carcinoma
  • Dermatofibrosarcoma Protuberans
  • Porocarcinoma

Publications

  • Intraocular Spread of Ocular Surface Squamous Neoplasia Presenting as a Postoperative Anterior Chamber Opacity after Excisional Biopsy. Case Rep Ophthalmol. 2023 Jan-Dec; 14(1):194-202.. View in PubMed
  • Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 03 02; 388(9):813-823.. View in PubMed
  • Prevalence and correlates of skin examination among ethnically diverse young adult survivors of childhood cancer. Cancer Med. 2023 04; 12(7):8557-8566.. View in PubMed
  • A retrospective analysis of rates of dermatology follow-up and new skin cancer diagnosis among solid organ transplant recipients during the COVID-19 pandemic. JAAD Int. 2023 Mar; 10:53-54.. View in PubMed
  • Social networks of oncology clinicians as a means for increasing survivorship clinic referral. Commun Med (Lond). 2022; 2:89.. View in PubMed
  • Development of a core outcome set for basal cell carcinoma. J Am Acad Dermatol. 2022 09; 87(3):573-581.. View in PubMed
  • Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. J Immunother Cancer. 2022 05; 10(5).. View in PubMed
  • Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions. Cancers (Basel). 2022 Mar 15; 14(6).. View in PubMed
  • Factors Associated With Hospitalization Among Breast Cancer Patients With COVID-19: A Diverse Multi-Center Los Angeles Cohort Study. Clin Breast Cancer. 2022 06; 22(4):e558-e566.. View in PubMed
  • Disparities in nonmelanoma skin cancer in Hispanic/Latino patients based on Mohs micrographic surgery defect size: A multicenter retrospective study. J Am Acad Dermatol. 2022 02; 86(2):353-358.. View in PubMed